MindMed

Psychedelic Inspired Medicines

Nasdaq	NEO	BÖRSE FRANKFURT
MNMD	MMED	MMQ

Disclaimer

Market and Industry Data

This presentation (the "Presentation") by Mind Medicine (MindMed) Inc. ("MindMed" or the "Company") includes market and industry data that has been obtained from third party sources, including industry publications. MindMed believes that the industry data is accurate and that the estimates and assumptions are reasonable, but there is no assurance as to the accuracy or completeness of this data. Third party sources generally state that the information contained therein has been obtained from sources believed to be reliable, but there is no assurance as to the accuracy or completeness of included information. Although the data is believed to be reliable, MindMed has not independently verified any of the data from third party sources referred to in this Presentation or ascertained the underlying economic assumptions relied upon by such sources. References in this Presentation to research reports or to articles and publications should be not construed as depicting the complete findings of the entire referenced report or article.

Cautionary Note on Forward-Looking Information

This Presentation contains "forward-looking statements" and "forward-looking information" within the meaning of applicable securities laws (collectively, "forward-looking information") with respect to MindMed and its subsidiaries. Statements in this Presentation that are forward-looking information are based on currently available competitive, financial, and economic data and operating plans as of the date of this Presentation but are subject to various risks and uncertainties concerning the specific factors disclosed herein. Often, but not always, forward-looking information can be identified by the use of words such as "plans", "expects", "is expected", "budget", "scheduled", "estimates", "forecasts", "intends", "anticipates", will", "projects", or "believes" or variations (including negative variations) of such words and phrases, or statements that certain actions, events, results or conditions "may", "could", "would", "might" or "will" be taken, occur or be achieved. Except for statements of historical fact, information contained herein constitutes forward-looking information, including, but not limited to: statements pertaining to the development and commercialization of any medicine or treatment, or the efficacy of either of the foregoing, the likelihood of success of any clinical trials or of obtaining FDA or other regulatory approvals, the likelihood of obtaining patents or the efficacy of such patents once granted, and the potential for the markets that MindMed is anticipating to access.

Forward-looking information is not a guarantee of future performance and is based upon a number of estimates and assumptions of management at the date the statements are made including, among other things, assumptions about: MindMed's ability to raise capital to complete its plans and fund its studies, the medical and commercial viability of the contemplated medicines and treatments being developed, and the ability of MindMed to raise additional capital in the future as MindMed continues to develop its products. While MindMed considers these assumptions to be reasonable, the assumptions are inherently subject to significant business, social, economic, political, regulatory, competitive and other risks and uncertainties, contingencies and other factors that could cause actual performance, achievements, actions, events, results or conditions to be materially different from those projected in the forward-looking information. These include the Company's history of negative cash flows; limited operating history; incurrence of future losses; availability of additional capital; lack of revenue; compliance with laws and regulations; difficulty associated with research and development; risks associated with clinical trials or studies; heightened regulatory scrutiny; early stage product development; clinical trial risks; regulatory approval processes; novelty of the psychedelic inspired medicines industry; as well as those risk factors discussed or referred to under the headings "Risk Factors" in the Company's final base shelf prospectus dated April 9, 2021 filed with the securities regulatory authorities in each of the provinces and territories of Canada and the Company's annual information form for the year ended December 31, 2020 filed with the securities regulatory authorities in each of the provinces and territories of Canada and available under the Company's profile on SEDAR at www.sedar.com and as described in the Company's U.S. registration statement on Form F-10 declared effective by the United States Securities and Exchange Commission (the "SEC") on April 12, 2021 and filed with the SEC on EDGAR at www.sec.gov. Many assumptions are based on factors and events that are not within the control of MindMed and there is no assurance they will prove to be correct.

The United States federal government regulates drugs through the Controlled Substances Act. The Company works with a non-hallucinogenic synthetic derivative of the psychedelic substance ibogaine, known as "18-MC", which is a synthetic organic molecule designed around a common coronaridine chemical backbone. 18-MC is not a Schedule I substance in the United States and the Company does not foresee it becoming a Schedule I substance due to its non-hallucinogenic properties. While the Company is focused on programs using psychedelic inspired compounds and classic psychedelics, the Company does not have any direct or indirect involvement with the illegal selling, production or distribution of any substances in the jurisdictions in which it operates. The Company is a neuro-pharmaceutical drug development company and does not deal with psychedelic substances except within laboratory and clinical trial settings conducted within approved regulatory frameworks. The Company's products will not be commercialized prior to applicable regulatory approval, which will only be granted if clinical evidence of safety and efficacy for the intended uses is successfully developed.

Although MindMed has attempted to identify important factors that could cause actual results, performance or achievements to differ materially from those contained in the forward-looking information, there can be other factors that cause results, performance or achievements not to be as anticipated, estimated or intended, including, but not limited to: MindMed not being able to obtain the necessary FDA and other approvals, inconclusive or negative results from clinical trials, MindMed electing to not proceed with any of the medicines or treatments discussed herein, and MindMed not being able to build production capacity should its trials be successful. To the extent any forward-looking information contains forecasts or financial outlooks, such information is being provided solely to enable a reader to assess MindMed's financial condition and its operational history and experience in the pharmaceutical industry. Readers are cautioned that this information may be not appropriate for any other purpose, including investment decisions. Such information, as with forward-looking information generally, is, without limitation, based on the assumptions and subject to the risks and other cautionary statements set out above. The actual results achieved will vary from the forecast or financial outlook results and the variations may be material. No representation or warranty of any kind is or can be made with respect to the accuracy or completeness of, and no representation or warranty should be inferred from, our projections or the assumptions underlying them.

There can be no assurance that such information will prove to be accurate or that management's expectations or estimates of future developments, circumstances or results will materialize. As a result of these risks and uncertainties, the results or events predicted in this forward-looking information may differ materially from actual results or events. Because of the risks, uncertainties and assumptions contained herein, readers should not read forward-looking information as guarantees of future performance or results. Nothing in this Presentation is, or should be relied upon as, a promise or representation as to the future. All amounts are in USD unless otherwise noted. Readers should not place undue reliance on forward-looking information. The forward-looking information in this Presentation is made as of the date of this Presentation. MindMed disclaims any intention or obligation to update or revise such information, except as required by applicable law, and MindMed does not assume any liability for disclosure relating to any other company mentioned herein. Investors are cautioned not to unduly rely on this forward-looking information and are encouraged to read MindMed's continuous disclosure documents, including its current annual information form, as well as its audited annual consolidated financial statements which are available on SEDAR at www.sedar.com and on EDGAR at www.sec.gov/edgar.

MindMed's securities have not been approved or disapproved by the SEC or by any state, provincial or other securities regulatory authority, nor has the SEC or any state, provincial or other securities regulatory authority passed on the accuracy or adequacy of this Presentation. Any representation to the contrary is a criminal offense.

Leadership: A Combination of Drug Developers & Technologists

JR Rahn

Co-Founder, CEO & Board Director

JR is a former Silicon Valley tech executive who realized that transformational solutions to mental illness and addiction might lie in psychedelic medicines. He spent 2 years researching and began personally investing in psychedelic research through his investment company. JR partnered with drug development veteran Stephen Hurst to start MindMed in 2019, assembling a leading clinical drug discovery and development team with vast experience conducting clinical trials and research on drug candidates derived from psychedelics. Before starting MindMed, JR worked in market expansion and operations at Uber.

Uber Y Combinator

Miri Halperin Wernli PhD

Executive President & Board Director

Miri co-founded Creso Pharma, a cannabis company, and listed the company on the Australian Stock exchange (ASX) in October 2016. Prior to founding Creso Pharma Dr. Halperin Wernli worked in clinical psychiatry in Swiss academic hospital settings and then held various global senior leadership positions in the pharma and biotech industries in Switzerland and in the US (Merck, Sharp and Dohme, Roche and Actelion pharmaceuticals) covering Product Development, R&D, and Strategic Marketing. Her extensive pharmaceutical industry and biomed research and development experience covers the full spectrum of areas and activities from Preclinical to Clinical Development and Strategy, to Drug Registration and Launch, across several Therapeutic Areas.

MERCK ACTELION Roche

Robert Barrow

Chief Development Officer

Rob is an accomplished pharmaceutical executive and clinical pharmacologist with over a decade of experience leading drug development programs in a variety of disease areas. Mr. Barrow previously served as Director of Drug Development & Discovery at Usona Institute, where he oversaw preclinical, clinical and regulatory development efforts for all of Usona's development programs. Prior to joining Usona, he served as Chief Operating Officer of Olatec Therapeutics where he oversaw the execution of numerous early- and late-stage clinical trials in the fields of analgesics, rheumatology, immunology and cardiovascular disease. Rob holds a Master's degree in Pharmacology from The Ohio State University and a Bachelor of Science degree from Wake Forest University, where he graduated summa cum laude.

Usona Institute OLATEC

Daniel R Karlin MD MA

Chief Medical Officer

Dan previously co-founded HealthMode in 2018 and served as CEO until its acquisition by MindMed. Before that, he built and led Clinical, Informatics, and Regulatory Strategy for Pfizer's Digital Medicine and Innovation Research Lab. He also served as Global Clinical Lead for psychiatry clinical compounds at Pfizer. Previously, he was the founder and Chief Medical Officer at Column Health, a leading technology-enabled psychiatry and addiction practice. He is a strategic advisor to multiple big pharma, and digital therapeutic companies. Dan is board Certified in Psychiatry, Addiction Medicine, and Clinical Informatics. He is an Asst. Prof. of Psychiatry at Tufts University School of Medicine. He graduated with degrees in Neuroscience and Behavior (BA), and Clinical Informatics (MA), Columbia University; Medicine (MD), University of Colorado School of Medicine.

Pfizer Tufts University

Carol Nast

Chief Operating Officer

Carol has spent her career in executive level positions with large multinational companies and early stage companies in the medical industry. She is a recognized expert in product development and commercialization and has extensive experience in the management of complex, multinational partner programs and has lead successfully the development and commercialization of over 100 products. Carol was COO at NuGen, a genomics company, and served in executive level positions at Inhale Therapeutics (Nektar), Syva (a division of Syntex Pharmaceuticals), BioRad and Pfizer. Her passion is the successful launch and adoption of breakthrough products in emerging markets that have significant impact by solving a vexing challenge.

NEKTAR Pfizer

Bradford Cross

Chief Technology Officer

Bradford previously co-founded HealthMode in 2018 and served as its CTO until its acquisition by MindMed. He is a career entrepreneur and investor with 15+ years at the intersection of AI and startups, and finance. Founded Prismatic in 2012, which powered part of LinkedIn's news feed as of 2015. Machine learning for personalization and content classification. Founded DCVC in 2011, which has grown into a $2B+ leading deep tech VC investing heavily at the intersection of computation and bio and spinning up dedicated DCVC bio fund. Founded Flightcaster in 2009, first AI Startup in YCombinator. He previously worked in distributed systems at Google 2007-2009. Brad earned degrees in Computer Science and Finance at Virginia Tech, and Mathematics at Berkeley.

Google Y Combinator

MindMed is a Mental Health Drug Development & Technology Company

New Asset Class

Psychedelics

- Novel MOAs
- Strong efficacy
- Clean safety profile
- Therapeutic surround

Pharmaceutical

- Rigorous scientific approach
- Strong infrastructure
- Clear regulatory pathways
- Drug and delivery optimization

Our Clinical Targets

MindMed

We target CNS disorders through :

Classic Psychedelics

(LSD, MDMA...)

Next-gen Psychedelic NCEs

(NCE Phenethylamines, NCE Tryptamines, Ibogaine Congeners)

Our Interconnected Strategy

- Diversified Clinical Pipeline of Classics & NCEs
- Targeting Accelerated Development Pathways
- IP & Market Protection
- Building Technology Platforms To Scale Future Launch of Medicines
- Pioneering Digital Measurement To Enable Reimbursement Models

MindMed's Mission Is Important



TITLE	DISASTER TYPE	STATE/TERRITORY	SIGNED DATE
Renewal of the Determination that a Public Health Emergency Exists Nationwide as the Result of the Continued Consequences of Coronavirus Disease 2019 (COVID-19) Pandemic	COVID-19	NATIONAL	APRIL 15, 2021
Renewal of the Determination that a Public Health Emergency Exists Nationwide as the Result of the Continued Consequences of the Opioid Crisis	OPIOID CRISIS	NATIONAL	APRIL 7, 2021

MindMed Appoints Dr. Sarah Vinson, MD to Board of Directors

Sarah Vinson MD

Board of Directors Member

Dr. Vinson is a Triple Board-Certified physician who specializes in adult, child & adolescent, and forensic psychiatry. She is the founder of Lorio Forensics, a multidisciplinary mental health expert consultation firm and of the Lorio Psych Group, a group mental healthcare practice. Dr. Vinson is an Associate Clinical Professor of Psychiatry and Pediatrics at Morehouse School of Medicine, where she is the Program Director of the Child & Adolescent Psychiatry Fellowship, and Adjunct Faculty at Emory University School of Medicine.

LORIO PSYCH GROUP

MOREHOUSE SCHOOL OF MEDICINE

EMORY UNIVERSITY SCHOOL OF MEDICINE

Dr. Vinson said, “Mental health is not merely a professional pursuit. It is my passion. I see the limitations of our current pharmacologic treatment options and recognize the importance – and necessity – of innovation. I’m grateful to be a part of MindMed’s tremendous undertaking.”

MindMed Bolsters Management Team

Appoints Peter Mack PhD as Vice President of Pharmaceutical Development

Peter Mack PhD

Vice President of Pharmaceutical Development

Peter will lead MindMed's product development activities across its entire portfolio of investigational drugs. In addition, Peter will oversee partnerships with Contract Manufacturing Development Organizations and other discovery efforts to support the advancement of MindMed's proprietary new chemical entities.

Peter joins MindMed from AstraZeneca, where he was the Director of Manufacturing for Inhalation Product Development. Peter previously worked at Pearl Therapeutics (acquired by AstraZeneca in 2013) where he helped pioneer the pharmaceutical development of inhaled combination therapies for highly prevalent respiratory diseases.

Peter holds a dual PhD in Medical Engineering / Medical Physics from Harvard Medical School and Massachusetts Institute of Technology (MIT), where he was a National Institute of Health (NIH) Biomechanics Training Grant Recipient. Peter also holds a Masters of Science in Mechanical Engineering from MIT. During his time in academia and the pharmaceutical industry, Peter contributed to numerous peer reviewed articles and patents.

MindMed 2.0

HealthMode Acquisition

MindMed + HealthMode

Dr. Dan Karlin
Chief Medical Officer

Pfizer

Tufts University

Bradford Cross
Chief Technology Officer

Google

Y Combinator

Prismatic
Learn interesting things every day

MindMed Listed on NASDAQ: MNMD

First Publicly Listed Psychedelic Biotech Company Now Listed in the United States

Nasdaq

$204M USD

Raised since inception (including warrants)

Project Lucy : Type C Update

Phase 2b

Generalized Anxiety Disorder

Our Development Principles

Rigorously Apply Professional Drug Development Principles Across The Portfolio

	We believe in
People	Talented drug developers & technologists with strong track records of success
Science	Scientific rigor and evidence based decision-making Following established paradigms for approval of new drugs
R&D Strategy	Robust, diverse and integrated R&D pipeline
Commercial & Technology Strategy	Focus on serving large markets with unmet medical needs Promoting accessibility and enabling scalability through tech platforms
Intellectual Property	Aggressive and informed pursuit of true innovation

Our Diversified Clinical Franchises & Development Process



Discover

Acquire new chemical entities and other psychedelics through strategic partnerships and collaborations

Develop

Take compounds through FDA regulated clinical trials while partnering with pharmaceutical companies

Deploy

Build strategic alliances with hospitals, research centers, and ultimately insurers that will license our protocols, technologies and drugs

Project Lucy

Project Lucy : LSD Single Use In Phase 2b for Anxiety Disorders

Phase 2b Clinical Trial of LSD in the Treatment of Anxiety

PSYCHIATRY FRANCHISE | **MM-120** *(LSD single use)* | **Indication:** Anxiety Disorders | **PHASE 2**

Enrolling 200 patients at up to 20 centers in the United States

Expected Start: Late 2021
Expected Readout: Late 2023

Patient Population

- HAM-A ≥ 20
- DSM-5: GAD or AdjD

Intervention

- Single dose
- Controlled clinical setting

Endpoints

- HAM-A change at 4 weeks
- HAM-A change at 8 weeks
- Multiple secondary and exploratory endpoints

Design

- Randomized
- Placebo controlled
- Dose-optimization study (0, 25, 50, 100, 200 ug)

Our Robust and Diverse Development Pipeline Differentiates Us from the Field

Pipeline Diversification Offers Access To Full Potential Of Psychedelic Inspired Medicines



Project Layla

18-MC for Substance Use Disorders

Phase 2 study in Patients with Opioid Withdrawal

ADDICTION FRANCHISE | **MM-110** *(18-MC)* | Indication: Substance Use Disorders | **PHASE 2**

Phase 2 Study: Late ‘21 or Early ‘22

Expected Potential Readout: Early 2023

Patient Population

- DSM-5 OUD
- Stabilized on morphine prior to withdrawal

Intervention

- Twice daily for 1 week
- Administered under observation (in-clinic)

Endpoints

- SOWS-Gossop upon morphine withdrawal (Days 1-5)

Design

- Randomized, placebo-controlled
- Dose-optimization

*Management estimates; actual timeline will depend on results, approvals and other factors outside MindMed’s control

Project Angie

Project Angie: MindMed's Pain Franchise

Advancing the development of psychedelics, including LSD, to treat pain conditions

Primary Clinical Target

- LSD in a severe pain indication
- FDA PIND meeting in 2nd half of 2021 (planned)

Subsequent Clinical Target

- Common, often debilitating, chronic pain syndrome
- Specifics of the clinical approach to be disclosed at a later date

Prior Evidence of Efficacy

- Includes a study co-authored by MindMed collaborating researchers Prof. Dr. Matthias Liechti and Dr. Kim Kuypers
- Demonstrated pain reducing effects of LSD at 20 ug[5]



Source: Ramaekers, J. G., Hutten, N., Mason, N. L., Dolder, P., Theunissen, E. L., Holze, F., Liechti, M. E., Feilding, A., & Kuypers, K. P. (2021). A low dose of lysergic acid diethylamide decreases pain perception in healthy volunteers. Journal of psychopharmacology (Oxford, England), 35(4), 398–405.

Pain: A Debilitating Symptom of Many Medical Conditions

Functional effects of chronic pain may lead to depression and opioid use disorders

Unmet Needs

- Pain effects a large, and growing, segment of the population
- Global market for analgesics expected to grow to over $31 billion by 2030[1]
- Overuse of opioids for pain has fueled the opioid epidemic

Why Psychedelics

- Evidence suggests that psychedelics offer a novel analgesic mechanism[2,3]
- Thought to exert effects on descending pain modulation pathways[2,3]
- Effect may be mediated via serotonin 2A (5-HT2a) receptor binding[2,3]
- Dysfunction in these pathways implicated in chronic pain syndromes[4]



Project Flow & UHB

Project Flow : LSD for Adult ADHD Phase 2a Clinical Trial

Study MMED007: Phase 2a POC Study of LSD in the Treatment of Adult ADHD

PSYCHIATRY FRANCHISE | **MM-290** *(LSD multi use)* | **Indication:** Adult ADHD | **PHASE 2**

Enrolling 56 patients at two centers in Europe

Expected Start: Late 2021
Expected Readout: Mid 2023

Patient Population

- AISRS > 25
- DSM-5: ADHD

Intervention

- Repeat dose (20 µg; q3d)
- Administered under observation (in-clinic or at-home)

Endpoints

- AISRS change at 4 weeks
- Multiple secondary and exploratory endpoints

Design

- Randomized
- Placebo controlled
- Parallel group

Discover Pipeline

Multimodal Data Acquisition Strategy for Discovery, Development, and Regulatory Submissions

MindMed entered into an exclusive license agreement with UHB covering LSD, MDMA and other psychedelics.

↓

MindMed is actively filing patents against this data in partnership with Liechti Lab.

Universitätsspital Basel | Department of Biomedicine

Discover Pipeline - Completed

Multimodal Data Acquisition Strategy for Discovery, Development, and Regulatory Submissions

ADVANCED TO DEVELOPMENT

COMPLETED STUDIES	ADVANCED TO DEVELOPMENT
LSD PK	LSD for Anxiety
LSD fMRI	
LSD LAM	
LSD LDR	
SERT-Psilocybin	
MDMA-reboxetine interaction	
MDMA-duloxetine interaction	
MDMA-clonidine interaction	
MDMA-carvedilol interaction	
MDMA-doxazosin interaction	
MDMA-methylphenidate interaction	
MDMA-methylphenidate comparison	

Discover Pipeline

Multimodal Data Acquisition Strategy for Discovery, Development, and Regulatory Submissions

STUDY	PHASE
LSD Psilocybin	Ongoing Phase I
LSD MDMA	Ongoing Phase I
LSD Ketanserin	Ongoing Phase I
LSD Psilocybin and Mescaline	Ongoing Phase I
LSD Anxiety	Ongoing Phase II
LSD Cluster Headaches	Ongoing Phase II
LSD Depression	Ongoing Phase II
DMT Regimen	Planned Phase I
LSD Bioequivalence	Planned Phase I
Mescaline dose response	Planned Phase I
MDMA like substances	Planned Phase I



Novel Chemical Entities as Pipeline Candidates

Developing Novel Compounds Derived from Psychedelic Substances or Synthesized from Existing Compounds

Engineering a portfolio of compounds & formulations that are expected to demonstrate variations in:

- Onset of action
- Duration of action
- Potency
- Safety
- Receptor Selectivity

Proprietary discovery efforts will target:

- Derivatives of existing compounds
- Enhanced versions of classic psychedelic compounds
- Compounds with expected combined psychedelic-empathogenic effect
- Drug candidates identified internally and with leading external partners

- Example Partnership: ***MindShift***
- A number of protectable NCEs ready for screening
- Several IP filings and synthesis efforts

MindMed is working on a new line of psychedelic inspired compounds for its clinical development pipeline

Albert Division

Albert is the Only Platform for Rapid Development and Deployment of Psychedelic Therapies Using Real World Data

We're focused on two main areas to apply our platform strategy

1. Consumer applications for patients and SaaS applications for providers at scale to provide new distribution and care models for comprehensive treatment plans from therapy to therapeutics.
2. Production machine learning measurement, diagnostic, and therapeutic models for personalized medicine learned from big real world data.

Applications and Machine Learning are both supported by the HealthMode acqusition.

Albert's Indication-specific Patient Apps Open Scalable Distribution Channels

Patient-facing apps enable new ways to bring psychedelic-assisted therapies to market

Leveraging the market's appetite for scalability

- Employers are looking for scalable cost effective mental health solutions with a productivity payback.
- This has lead to lightweight EAPs, counseling, and generic wellness apps as low cost alternatives that aren't necessarily evidence based with respect to either clinical or productivity outcomes.
- We leverage this demand for scalability as an opportunity to wedge in through indication-specific, evidence-based apps that make the patient discovery and care process more efficient and create new distribution models for therapists and therapeutics.



Albert Uses Digital Measures, Diagnostics & Therapeutics To Enable Care and Reimbursement

MindMed Reimbursement Cycle:

1. Build measurement, diagnostic and therapeutic models using real world data from public sources and our own apps.
2. Subsequently, MindMed validates measures, diagnostics, and interventions through clinical studies run on internal application channels.
3. Next-gen applications intended to support full patient and provider journeys including sessions and real world monitoring.
4. Embedded measures, diagnostics, and therapeutics intended to enable closed-loop value-based care and strong evidence-based commercialization strategies with payers.



Albert Application Platform Enables Rapid Multi-App Development

Leveraging and Extending HealthMode's architecture for client, server, ML services, and infrastructure automation

Application Clients

- IOS, Android, Web, SmartWatch
- Dynamic exercises and video capabilities
- Easy for product engineers to add studies with informed consent

Application Services

- Product engineers can easily add their own handlers in Django and Node.js
- Baked in support for HealthTech apps including studies, security, compliance, etc
- Flexible client-server utilization of streaming device data

Core IP Services

- Robust Terraform/Kubernetes automated infrastructure
- Baked in security and compliance
- Easy to spin up new applications, services, data processing and modeling tasks

Infrastructure

- Easy to train and deploy new Python models
- State of the art deep networks in core data domains like audio, text, behavioral, biological, etc
- Platform for bootstrapping from online public RWD and spinning up new medical expert annotation tasks

Albert Models Relevant Data for Measurement, Diagnostics, and Therapeutics

Data	Models	Applications
Audio*	Albert Machine Learning	Anxiety
Text	Measurements	Addiction
Behavioral*	Diagnostics	PTSD
Genomic	Therapeutics	ADHD
Biological		Pain
Mobile*		
Smartwatch*		
Partner Integrations		

*enabled by HealthMode acquisition

Albert is Our Platform for Rapid Development and Deployment of Psychedelic Therapies Using Real World Data

How we Apply Machine Learning:

Patients' participation at scale enables a platform for real world evidence based product iteration, and clinical studies to validate digital measures, diagnostics, and therapeutics.

→

Production models for personalized medicine can only be learned from big real world data, because datasets limited to the scale of 10s or 100s of patients in clinical studies often aren't large enough for modern models.

Key Insight

FDA is increasingly open to contemporary approaches leveraging real world data and real world evidence.

Financials

Financial Overview

Results in USD

Highlights

- Listed on Nasdaq under the symbol MNMD
- MindMed closed its acquisition of HealthMode - Net cash used for the acquisition of HealthMode - $0.5 million (primarily a stock deal)
- MindMed closed an upsized financing of $92 million CAD ($73 million USD)
- MindMed closed a subsequent private placement of $19.5 million CAD ($15.4 million USD)
- MindMed announced its inclusion in FTSE Russell Indexes

Total Assets	$201 Million	Net & Comp. Loss	$14 Million
Total Cash	$10 Million	Total Cash Burn	$10 Million

(Expressed in thousands of United States Dollars)	March 31, 2021 (Unaudited)	December 31, 2020 (Audited)
Cash	159,919	80,094
Prepaid & other current assets	2,297	875
Total current assets	162,287	80,969
Non-current assets	38,500	-
Total assets	200,794	85,644
Current liabilities	6,450	2,377
Non-current liabilities	6,750	-
Total liabilities	13,200	2,377
Share capital	216,687	105,604
Warrants	22,880	15,871
Contributed surplus	3,244	2,321
Accumulated other comp. income	441	284
Total shareholders' equity	187,594	83,267
Total liabilities and shareholders' equity	200,794	85,644

MindMed

Sources

1. IQVIA. (2021, May). IQVIA Global Annual Sales Report.
2. Tao, Z. Y., Wang, P. X., Wei, S. Q., Traub, R. J., Li, J. F., & Cao, D. Y. (2019). The Role of Descending Pain Modulation in Chronic Primary Pain: Potential Application of Drugs Targeting Serotonergic System. Neural plasticity, 2019, 1389296. https://doi.org/10.1155/2019/1389296
3. Castellanos, J. P., Woolley, C., Bruno, K. A., Zeidan, F., Halberstadt, A., & Furnish, T. (2020). Chronic pain and psychedelics: a review and proposed mechanism of action. Regional anesthesia and pain medicine, 45(7), 486–494. https://doi.org/10.1136/rapm-2020-101273
4. Ossipov, M. H., Morimura, K., & Porreca, F. (2014). Descending pain modulation and chronification of pain. Current opinion in supportive and palliative care, 8(2), 143–151. https://doi.org/10.1097/SPC.0000000000000055
5. Ramaekers, J. G., Hutten, N., Mason, N. L., Dolder, P., Theunissen, E. L., Holze, F., Liechti, M. E., Feilding, A., & Kuypers, K. P. (2021). A low dose of lysergic acid diethylamide decreases pain perception in healthy volunteers. Journal of psychopharmacology (Oxford, England), 35(4), 398–405. https://doi.org/10.1177/0269881120940937